Pioglitazone is an effective treatment option in clinical practice for managing type 2 diabetes mellitus. It is challenged by a lot of adverse effects, primarily body weight gain, peripheral edema, as well as congestive heart failure.
Case Report:
This is a case of a 76-year-old woman with no evidence of cardiac disease, who developed edema as well as bilateral pleural effusion after using pioglitazone. She got a weight decrease and complete resolution of the pleural effusion after stopping use of pioglitazone and rational use of diuretics.
Conclusion:
Common side effects of pioglitazone have been widely reported. However, little attention was drawn on pleural effusion in diabetic patients with no pre-existing heart dysfunction. In this case, we show the use of pioglitazone results in pleural effusion, with emphasis on the clinical recognition and management.
Get full access to this article
View all access options for this article.
References
1.
YasminS, JayaprakashV. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present. Eur J Med Chem, 2017; 126:879–893.
2.
MillerJL. FDA approves pioglitazone for diabetes. Am J Health Syst Pharm, 1999; 56:1698.
3.
DormandyJ, BhattacharyaM, van TroostenburgDBA. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive. Drug Saf, 2009; 32:187–202.
4.
ChenYW, ChenYC, WuCJ, et al.Massive bilateral pleural effusion associated with use of pioglitazone. Clin Ther, 2008; 30:1485–1489.
5.
MunirA, KalathilS, NagS. Pleural effusion caused by pioglitazone: Case report. Pract Diab Int, 2011; 28:160.
6.
KernanWN, ViscoliCM, FurieKL, et al.Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med, 2016; 374:1321–1331.
7.
NissenSE, NichollsSJ, WolskiK, et al.Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA, 2008; 299:1561–1573.
8.
CusiK, OrsakB, BrilF, et al.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med, 2016; 165:305–315.
9.
AlamF, IslamMA, MohamedM, et al.Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: A systematic review and meta-analysis of randomised controlled trials. Sci Rep, 2019; 9:5389.
10.
HoritaS, NakamuraM, SatohN, et al.Thiazolidinediones and edema: Recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention. PPAR Res, 2015; 2015:646423.
11.
NakamuraA, OsonoiT, TerauchiY. Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig, 2010; 1:208–211.
12.
BerlieHD, KalusJS, JaberLA. Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Res Clin Pract, 2007; 76:279–289.
13.
KawashimaS, KanetoH, SakamotoK, et al.Acute progression of severe insulin edema accompanied by pericardial and pleural effusion in a patient with type 2 diabetes. Diabetes Res Clin Pract, 2008; 81:e18–e19.
14.
KalambokisGN, TsatsoulisAA, TsianosEV. The edematogenic properties of insulin. Am J Kidney Dis, 2004; 44:575–590.
15.
KouritasVK, HatzoglouC, IoannouM, et al.Insulin alters the permeability of sheep pleura. Exp Clin Endocrinol Diabetes, 2010; 118:304–309.
16.
ZendaT, MuraseY, YoshidaI, et al.Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e., cause insulin oedema?. Eur J Gastroenterol Hepatol, 2003; 15:545–549.
17.
LeeP, KinsellaJ, BorkmanM, et al.Bilateral pleural effusions, ascites, and facial and peripheral oedema in a 19-year-old woman 2 weeks following commencement of insulin lispro and detemir—an unusual presentation of insulin oedema. Diabet Med, 2007; 24:1282–1285.
18.
CharbonnelB, DeFronzoR, DavidsonJ, et al.Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab, 2010; 95:2163–2171.
19.
NaranjoCA, BustoU, SellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981; 30:239–245.
20.
ChangCS, TsaiPJ, SungJM, et al.Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. Am J Pathol, 2014; 184:442–453.
